JP2020519621A5 - - Google Patents

Download PDF

Info

Publication number
JP2020519621A5
JP2020519621A5 JP2019561977A JP2019561977A JP2020519621A5 JP 2020519621 A5 JP2020519621 A5 JP 2020519621A5 JP 2019561977 A JP2019561977 A JP 2019561977A JP 2019561977 A JP2019561977 A JP 2019561977A JP 2020519621 A5 JP2020519621 A5 JP 2020519621A5
Authority
JP
Japan
Prior art keywords
cancer
subject
medicament according
drug
inhibits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019561977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519621A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/031876 external-priority patent/WO2018208968A1/en
Publication of JP2020519621A publication Critical patent/JP2020519621A/ja
Publication of JP2020519621A5 publication Critical patent/JP2020519621A5/ja
Priority to JP2023067482A priority Critical patent/JP7717749B2/ja
Pending legal-status Critical Current

Links

JP2019561977A 2017-05-09 2018-05-09 癌を治療するための併用療法 Pending JP2020519621A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023067482A JP7717749B2 (ja) 2017-05-09 2023-04-17 癌を治療するための併用療法

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201762503879P 2017-05-09 2017-05-09
US62/503,879 2017-05-09
US201762508359P 2017-05-18 2017-05-18
US62/508,359 2017-05-18
US201762556255P 2017-09-08 2017-09-08
US62/556,255 2017-09-08
US201862634789P 2018-02-23 2018-02-23
US62/634,789 2018-02-23
US201862646332P 2018-03-21 2018-03-21
US62/646,332 2018-03-21
US201862648327P 2018-03-26 2018-03-26
US62/648,327 2018-03-26
PCT/US2018/031876 WO2018208968A1 (en) 2017-05-09 2018-05-09 Combination therapies for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023067482A Division JP7717749B2 (ja) 2017-05-09 2023-04-17 癌を治療するための併用療法

Publications (2)

Publication Number Publication Date
JP2020519621A JP2020519621A (ja) 2020-07-02
JP2020519621A5 true JP2020519621A5 (cg-RX-API-DMAC7.html) 2021-06-10

Family

ID=64105496

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019561977A Pending JP2020519621A (ja) 2017-05-09 2018-05-09 癌を治療するための併用療法
JP2023067482A Active JP7717749B2 (ja) 2017-05-09 2023-04-17 癌を治療するための併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023067482A Active JP7717749B2 (ja) 2017-05-09 2023-04-17 癌を治療するための併用療法

Country Status (14)

Country Link
US (2) US12156872B2 (cg-RX-API-DMAC7.html)
EP (1) EP3621592A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020519621A (cg-RX-API-DMAC7.html)
KR (1) KR20200018436A (cg-RX-API-DMAC7.html)
CN (1) CN110831580A (cg-RX-API-DMAC7.html)
AU (3) AU2018264992A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019023591A2 (cg-RX-API-DMAC7.html)
CA (1) CA3063201A1 (cg-RX-API-DMAC7.html)
IL (1) IL270511B2 (cg-RX-API-DMAC7.html)
MA (1) MA48637A (cg-RX-API-DMAC7.html)
MX (1) MX2019013373A (cg-RX-API-DMAC7.html)
TW (2) TW202444417A (cg-RX-API-DMAC7.html)
WO (1) WO2018208968A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201907395B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
WO2018200517A1 (en) 2017-04-24 2018-11-01 Tesaro, Inc. Methods of manufacturing of niraparib
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
WO2019067978A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. POLYTHERAPIES FOR THE TREATMENT OF CANCER
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
TW201938165A (zh) * 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
JP7805005B2 (ja) * 2019-12-31 2026-01-23 フーカン(シャンハイ) ヘルス テクノロジー カンパニー、 リミテッド 腫瘍治療の医薬組み合わせとその使用
AU2022233411A1 (en) * 2021-03-12 2023-09-14 Akeso Biopharma, Inc. Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof
WO2022271547A1 (en) 2021-06-21 2022-12-29 Tesaro, Inc. Combination treatment of cancer with a parp inhibitor and a lipophilic statin
US20250352534A1 (en) 2022-02-15 2025-11-20 Tesaro, Inc. Use of Niraparib for the Treatment of Brain Cancer
WO2025128263A1 (en) * 2023-12-15 2025-06-19 Pharmaessentia Corporation Anti-pd-1 monoclonal antibody and methods of preparation thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059571T3 (es) 1988-01-19 1994-11-16 Takeda Chemical Industries Ltd Fumagilina como agente angiostatico.
DE68915900T2 (de) 1988-09-01 1994-11-24 Childrens Medical Center Angiogenese hemmendes Mittel.
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US9707302B2 (en) * 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US20090275619A1 (en) 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
AU2008321382A1 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
WO2009064738A2 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
EP2240466B1 (en) 2008-01-08 2015-07-29 Merck Sharp & Dohme Limited Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
US9078864B2 (en) 2008-01-08 2015-07-14 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
AR075239A1 (es) 2009-02-04 2011-03-16 Bipar Sciences Inc Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
WO2011153383A1 (en) * 2010-06-04 2011-12-08 Bipar Science, Inc. Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
EP3327148B1 (en) 2010-06-18 2021-03-17 Myriad Genetics, Inc. Methods of predicting the status of brca1 and brca2 genes in a cancer cell
ES2704303T3 (es) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
CA2742342A1 (en) 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
CA2867434C (en) 2012-06-07 2021-10-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
EP2928473B1 (en) 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
DK2928865T3 (en) 2012-12-07 2018-06-18 Merck Sharp & Dohme BIOCATALYTIC TRANSAMINATION PROCEDURE
WO2014138101A1 (en) 2013-03-04 2014-09-12 Board Of Regents, The University Of Texas System Gene signature to predict homologous recombination (hr) deficient cancer
US20150071910A1 (en) 2013-03-15 2015-03-12 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CA2931181C (en) * 2013-12-09 2023-01-24 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
JP6663350B2 (ja) 2014-01-16 2020-03-11 クロヴィス・オンコロジー,インコーポレーテッド ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのparp阻害剤の使用
US20170175197A1 (en) 2014-01-29 2017-06-22 Caris Mpi, Inc. Molecular profiling of immune modulators
US10570202B2 (en) 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
KR20160146747A (ko) * 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
JP6648040B2 (ja) 2014-05-28 2020-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリン及びポリ(adpリボース)ポリメラーゼ(parp)阻害剤の使用
US20150344968A1 (en) * 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
PL3277321T3 (pl) 2015-04-01 2024-11-18 Anaptysbio, Inc. Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
WO2016176503A1 (en) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
EP3303397A1 (en) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
SG10201913073YA (en) * 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
CN108883115A (zh) 2015-10-26 2018-11-23 麦迪韦逊科技有限责任公司 用parp抑制剂治疗小细胞肺癌
WO2017142871A1 (en) 2016-02-15 2017-08-24 Astrazeneca Ab Methods comprising fixed intermittent dosing of cediranib
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
US11202782B2 (en) 2016-09-27 2021-12-21 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors
MA50677A (fr) 2016-11-01 2021-07-14 Anaptysbio Inc Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
CN110049777A (zh) 2016-11-01 2019-07-23 安奈普泰斯生物有限公司 针对程序性死亡-1(pd-1)的抗体
AU2018205401B2 (en) * 2017-01-09 2025-01-02 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
PT3565844T (pt) 2017-01-09 2023-05-02 Tesaro Inc Métodos de tratamento de cancro com anticorpos anti-pd-1
EP3606523A1 (en) 2017-03-27 2020-02-12 Tesaro, Inc. Niraparib formulations
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
WO2018200517A1 (en) 2017-04-24 2018-11-01 Tesaro, Inc. Methods of manufacturing of niraparib
TWI791519B (zh) 2017-04-27 2023-02-11 美商提薩羅有限公司 針對淋巴細胞活化基因-3(lag-3)之抗體藥劑及其用途
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
US20200129482A1 (en) 2017-06-26 2020-04-30 Abbvie Inc. Treatment of non-small cell lung cancer
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
WO2019067978A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. POLYTHERAPIES FOR THE TREATMENT OF CANCER
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
TW201929902A (zh) 2017-12-27 2019-08-01 美商提薩羅有限公司 治療癌症之方法
BR112020015909A2 (pt) 2018-02-05 2020-12-15 Tesaro, Inc. Formulações pediátricas de niraparib e métodos de tratamento pediátrico
EA201992594A1 (ru) 2018-03-26 2020-03-20 Тесаро, Инк. Комбинированные терапии для лечения рака
US11970530B2 (en) 2020-08-13 2024-04-30 Astrazeneca Ab Methods of treating homologous recombination deficient cancer

Similar Documents

Publication Publication Date Title
JP2020503364A5 (cg-RX-API-DMAC7.html)
JP2020536066A5 (cg-RX-API-DMAC7.html)
McCormack Nintedanib: first global approval
KR101258426B1 (ko) 세포 증식과 관련된 질환 치료용 배합물
JP2022087185A5 (cg-RX-API-DMAC7.html)
CN111093706B (zh) Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途
Jing et al. Aurora kinase inhibitors: a patent review (2014-2020)
JP2020536869A5 (cg-RX-API-DMAC7.html)
Meiss et al. Vismodegib
JP2018527383A5 (cg-RX-API-DMAC7.html)
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
Li et al. Combination of anti-EGFR and anti-VEGF drugs for the treatment of previously treated metastatic colorectal cancer: a case report and literature review
WO2022055895A1 (en) Treatment regimens for exon-20 insertion mutant egfr cancers
Gryziak et al. Milestones in the treatment of hepatocellular carcinoma: A systematic review.
CN117794540A (zh) 用于治疗b细胞恶性肿瘤的组合物
Burns et al. CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo
JP2025517908A5 (cg-RX-API-DMAC7.html)
Krajewska et al. Drug safety evaluation of lenvatinib for thyroid cancer
Deiana et al. Advances in target drugs and immunotherapy for biliary tract cancer
Schvartsman et al. An unusual case of central retinal vein occlusion and review of the toxicity profile of regorafenib in GIST patients
WO2020106898A1 (en) Pharmaceutical methods
CN112543646B (zh) 一种抗pd-1抗体和法米替尼联合在制备治疗肿瘤的药物中的用途
Zhang et al. Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive‐stage small‐cell lung cancer patients (DURABLE study)
Landi et al. Ceritinib for the treatment of non-small cell lung cancer
WO2023051606A1 (zh) Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途